Events & Presentations

Investors

Events & Presentations

Upcoming Events
More events are coming soon.
Archived Events
Date Event Details
Mar 18, 2020 4:00 PM EDT
Oppenheimer 30th Annual Healthcare Conference
New York

Conference Presentations cancelled due to COVID-19

Mar 17, 2020 2:00 PM EDT
5th Annual Oligonucleotide & Precision Therapeutics Congress
Cambridge

Conference Presentations cancelled due to COVID-19

Mar 11, 2020 11:15 AM EDT
Barclays Global Healthcare Conference
Miami
Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will participate in a hybrid podium/fireside chat presentation
Feb 5, 2020 4:30 PM EST
Arrowhead Pharmaceuticals 2020 First Quarter Results
Dec 10, 2019 6:00 PM HST
HEP DART 2019

Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver an oral presentation titled, “Where will RNAi fit in the era of finite therapies”

Dec 3, 2019 11:00 AM EST
Piper Jaffray 31st Annual Healthcare Conference
Fireside chat cancelled

Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation with Edward Tenthoff, managing director and senior research analyst at Piper Jaffray

Nov 25, 2019 4:30 PM EST
Arrowhead Pharmaceuticals 2019 Year End Results
Nov 18, 2019
American Heart Association Scientific Sessions 2019
Philadelphia

November 18, 9:32 a.m. EST – Dr. Christie Ballantyne, Baylor Coll Med, Houston, TX, will deliver an oral presentation titled, “RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides”

November 18, 9:38 a.m. EST – Dr. Gerald Watts, Univ of Western Australia, Royal Perth Hosp, Perth, Australia, will deliver an oral presentation titled, “RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects”

Nov 8 - Nov 12, 2019
The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
Boston

Dose Response with the RNA Interference Therapy JNJ-3989 Combined with Nucleos(t)ide Analogue Treatment in Expanded Cohorts of Patients with Chronic Hepatitis B

  • Publication Number: 0696
  • Session: Hepatitis B - Therapeutics: New Agents
  • Session Date and Time: November 8, 2019 from 8:00 AM to 5:30 PM EST
  • Location: Hynes Convention Center, Hall B
  • Authors: Edward Gane, et al.

FIRST CLINICAL EXPERIENCE WITH RNA INTERFERENCE [RNAi]-BASED TRIPLE COMBINATION THERAPY IN CHRONIC HEPATITIS B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) AND A NUCLEOS(T)IDE ANALOGUE (NA)

  • Publication Number: LP4
  • Session: Late-Breaking Poster Session
  • Session Date and Time: November 11, 2019 from 8:00 AM to 5:30 PM EST
  • Location: Hynes Convention Center, Hall B
  • Authors: Man-Fung Yuen, et al.
Oct 31, 2019 11:15 AM CDT
North American Cystic Fibrosis Conference
Nashville
Erik Bush, Ph.D., Arrowhead’s vice president of extra-hepatic targeting, will deliver a poster presentation titled, “Therapeutic Inhibition of ENaC With a Lung-Targeted RNAi Molecule Delivery Platform Preserves Normal Mucus Clearance in a Mucostatic Sheep Model of Cystic Fibrosis”